CTRI/2013/08/003933已完成4 期
tilizing Ranibizumab intravitreal Injection in a real world setting-A multicentre, open-label, prospective, observational study to evaluate effectiveness and safety of repeated intravitreal injections (IVI) of Lucentis® (ranibizumab) in patients with neovascular age-related macular degeneration (AMD) over a 12-month observational period in a real-world setting. - UNVEI
ovartis India Limited0 个研究点目标入组 3,000 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 3,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •ï¿½Presence of exudative age-related macular degeneration.
- •ï¿½Patients for whome a therapy with Lucentis� is medically indicated.
- •ï¿½Patients who consent to have their data collected. Patients will not need to consent to taking the drug, as their treatment is decided before entry into the study and is part of their medical care.
排除标准
- •Any contra-indication according to local Summary of Product Characteristics or Prescribing Information (SmPC or PI) of Lucentis®.
研究者
相似试验
进行中（未招募）
不适用
Injection of Lucentis (Ranibizumab) in the vitreous body of the eye after eye surgery and application of recombinant tissue plasminogen activator (rtPA) in patients with submacular bleeding complications suffering from wet age-related macular degeneration (AMD).exsudative age-related macular degeneration with acut submacular hemorrhageMedDRA version: 16.1Level: LLTClassification code 10055305Term: Macula lutea hemorrhageSystem Organ Class: 100000004853MedDRA version: 16.1Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 100000004853EUCTR2010-018637-21-DEniversitätsklinikum Schleswig-Holstein UKSH
招募中
2 期
Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).exsudative age-related macular degeneration with acut submacular hemorrhageH35.3H35.6Degeneration of macula and posterior poleRetinal haemorrhageDRKS00005090niversitätsklinikum Schleswig-Holstein Campus Kiel15
进行中（未招募）
不适用
Injection sous-conjonctivale de ranibizumab (Lucentis®) dans le traitement de la néovascularisation cornéenne : étude pilote de phase I/II - KerNéonéovascularisation cornéenneMedDRA version: 12.1Level: LLTClassification code 10055665Term: Corneal neovascularisationEUCTR2010-020683-38-FRCHU de Bordeaux
已完成
不适用
Comparison of intravitreal ranibizumab injection with or without tissue plasminogen activator in the treatment of type 2 choroidal neovascularizationeovascular age-related macular degenerationJPRN-UMIN000017081Department of Ophthalmology and Visual Science Nagoya City University Graduate School of Medical Sciences20
进行中（未招募）
1 期
Injections into the eye (drug Lucentis) in diabetic patients in whom no further treatment is currently available in clinic when they have developed swelling of the centre of the macula associated with lack of blood supply.Ischaemic Diabetic Macular OedemaMedDRA version: 14.1Level: LLTClassification code 10057915Term: Diabetic macular oedemaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: PTClassification code 10012689Term: Diabetic retinopathySystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: PTClassification code 10012688Term: Diabetic retinal oedemaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10054372Term: Diabetic retinal edemaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10054109Term: Non-proliferative diabetic retinopathySystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: PTClassification code 10012661Term: Diabetic eye diseaseSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10038925Term: Retinopathy diabeticSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: HLGTClassification code 10012653Term: Diabetic complicationsSystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 14.1Level: HLTClassification code 10012657Term: Diabetic complications ophthalmicSystem Organ Class: 10014698 - Endocrine disordersEUCTR2013-000031-27-GBMoorfields Eye Hospital80